No Data
No Data
Intra-Cellular surged nearly 35%! Johnson & Johnson plans to spend $10 billion to acquire the company, marking the largest Biotechnology merger in nearly two years!
This is the largest Trade in the biotechnology Industry in nearly two years, and it is also the first Biomedical merger exceeding 10 billion dollars since 2024, indicating a resurgence in merger and acquisition activities in the Medical Care sector. Goldman Sachs stated that the potential financing capacity of large Biopharmaceutical companies is at least 500 billion dollars, providing significant operational space for R&D investment, merger expansion, and more.
Shareholder Alert: Ademi LLP Investigates Whether Intra-Cellular Therapies, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Top 20 by transaction amount | ITCI rose over 34%, Johnson & Johnson plans to acquire the company; Semiconductor stocks fell, Micron dropped over 4%, Taiwan Semiconductor dropped over 3%.
On Monday, the trading volume of the US stock market ranked first, NVIDIA closed down 1.97%, with a transaction volume of 26.797 billion dollars; second place Tesla closed up 2.17%, with a transaction volume of 26.066 billion dollars; fifth place Meta Platforms closed down 1.22%, with a transaction volume of 6.476 billion dollars.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update
Baird Downgrades Intra-Cellular Therapies to Neutral From Outperform, $132 Price Target